250 related articles for article (PubMed ID: 24305878)
41. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
[TBL] [Abstract][Full Text] [Related]
42. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
[TBL] [Abstract][Full Text] [Related]
43. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
[TBL] [Abstract][Full Text] [Related]
44. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
[TBL] [Abstract][Full Text] [Related]
45. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
[TBL] [Abstract][Full Text] [Related]
46. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
[TBL] [Abstract][Full Text] [Related]
47. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
Sang J; Acquaviva J; Friedland JC; Smith DL; Sequeira M; Zhang C; Jiang Q; Xue L; Lovly CM; Jimenez JP; Shaw AT; Doebele RC; He S; Bates RC; Camidge DR; Morris SW; El-Hariry I; Proia DA
Cancer Discov; 2013 Apr; 3(4):430-43. PubMed ID: 23533265
[TBL] [Abstract][Full Text] [Related]
48. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
49. Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes.
Fleuren EDG; Vlenterie M; van der Graaf WTA; Hillebrandt-Roeffen MHS; Blackburn J; Ma X; Chan H; Magias MC; van Erp A; van Houdt L; Cebeci SAS; van de Ven A; Flucke UE; Heyer EE; Thomas DM; Lord CJ; Marini KD; Vaghjiani V; Mercer TR; Cain JE; Wu J; Versleijen-Jonkers YMH; Daly RJ
Cancer Res; 2017 Aug; 77(16):4279-4292. PubMed ID: 28634201
[TBL] [Abstract][Full Text] [Related]
50. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Ma PC; Jagadeeswaran R; Jagadeesh S; Tretiakova MS; Nallasura V; Fox EA; Hansen M; Schaefer E; Naoki K; Lader A; Richards W; Sugarbaker D; Husain AN; Christensen JG; Salgia R
Cancer Res; 2005 Feb; 65(4):1479-88. PubMed ID: 15735036
[TBL] [Abstract][Full Text] [Related]
51. PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer.
Thu YM; Suzawa K; Tomida S; Ochi K; Tsudaka S; Takatsu F; Date K; Matsuda N; Iwata K; Nakata K; Shien K; Yamamoto H; Okazaki M; Sugimoto S; Toyooka S
PLoS One; 2024; 19(5):e0300644. PubMed ID: 38758826
[TBL] [Abstract][Full Text] [Related]
52. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
Reungwetwattana T; Liang Y; Zhu V; Ou SI
Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.
Matzke-Ogi A; Jannasch K; Shatirishvili M; Fuchs B; Chiblak S; Morton J; Tawk B; Lindner T; Sansom O; Alves F; Warth A; Schwager C; Mier W; Kleeff J; Ponta H; Abdollahi A; Orian-Rousseau V
Gastroenterology; 2016 Feb; 150(2):513-25.e10. PubMed ID: 26597578
[TBL] [Abstract][Full Text] [Related]
54. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.
Calles A; Kwiatkowski N; Cammarata BK; Ercan D; Gray NS; Jänne PA
Mol Oncol; 2015 Jan; 9(1):260-9. PubMed ID: 25226813
[TBL] [Abstract][Full Text] [Related]
55. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
[TBL] [Abstract][Full Text] [Related]
56. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
57. MicroRNA-19a functions as an oncogenic microRNA in non-small cell lung cancer by targeting the suppressor of cytokine signaling 1 and mediating STAT3 activation.
Wang X; Chen Z
Int J Mol Med; 2015 Mar; 35(3):839-46. PubMed ID: 25604748
[TBL] [Abstract][Full Text] [Related]
58. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
59. The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy.
Clémenson C; Chargari C; Liu W; Mondini M; Ferté C; Burbridge MF; Cattan V; Jacquet-Bescond A; Deutsch E
Mol Cancer Ther; 2017 Oct; 16(10):2107-2119. PubMed ID: 28619752
[TBL] [Abstract][Full Text] [Related]
60. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice.
Colon J; Basha MR; Madero-Visbal R; Konduri S; Baker CH; Herrera LJ; Safe S; Sheikh-Hamad D; Abudayyeh A; Alvarado B; Abdelrahim M
Invest New Drugs; 2011 Feb; 29(1):41-51. PubMed ID: 19851711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
